Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach

Rifaximin, with its low systemic absorption, may represent a treatment of choice for irritable bowel syndrome (IBS), mainly due to its ability to act on IBS pathogenesis, through the influence on gut microbiota. The aim of the present study was to assess, by biomolecular tools, the rifaximin active...

Descripción completa

Detalles Bibliográficos
Autores principales: Soldi, Sara, Vasileiadis, Sotirios, Uggeri, Francesca, Campanale, Mariachiara, Morelli, Lorenzo, Fogli, Maria Vittoria, Calanni, Fiorella, Grimaldi, Maria, Gasbarrini, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675645/
https://www.ncbi.nlm.nih.gov/pubmed/26673000
http://dx.doi.org/10.2147/CEG.S89999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675645/
https://www.ncbi.nlm.nih.gov/pubmed/26673000
http://dx.doi.org/10.2147/CEG.S89999

Ejemplares similares